TSE:APS Aptose Biosciences (APS) Stock Price, News & Analysis C$2.25 0.00 (0.00%) As of 06/26/2026 03:55 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsBuy This Stock About Aptose Biosciences Stock (TSE:APS) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Aptose Biosciences alerts:Sign Up Key Stats Today's RangeC$2.20▼C$2.2550-Day RangeC$2.00▼C$2.3852-Week RangeC$1.08▼C$2.59Volume305 shsAverage Volume3,663 shsMarket CapitalizationC$5.74 millionP/E RatioN/ADividend Yield0.39%Price TargetN/AConsensus RatingHold Company Overview Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies. The company has an agreement with CrystalGenomics, Inc. to research, develop, and commercialize CG026806, a non-covalent small molecule therapeutic agent, which is in preclinical stage for the treatment of acute myeloid leukemia and chronic lymphocytic leukemia/mantle cell lymphoma. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was founded in 1986 and is headquartered in Mississauga, Canada. Read More Receive APS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Aptose Biosciences and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. APS Stock News HeadlinesAptose Presents Safety, Response, and MRD Clinical Data from TUSCANY Phase 1/2 Clinical Trial of Tuspetinib Triplet Therapy in Newly Diagnosed AML at the 2026 EHA Congress in ...June 15, 2026 | markets.businessinsider.comAptose Biosciences, Inc.: Aptose Reports First Quarter 2026 ResultsMay 14, 2026 | finanznachrichten.deSolar is dead. Here’s what replaces it.Starting July 4th, every new solar and wind project in America loses its federal tax credits. But one zero-carbon energy source retains full government backing for eight more years - and it runs around the clock without batteries. Investment in this sector has surged 100x in seven years. The Pentagon named it a top energy priority, California mandated it, and Google, Meta, and Berkshire Hathaway are already under contract. One company controls the entire chain from the ground to the grid.June 30 at 1:00 AM | Behind the Markets (Ad)Aptose Biosciences Announces Results of Special Shareholders Meeting; Announces Receipt of Final Court Approval of Plan of Arrangement; Reports Year End 2025 Results and ...March 31, 2026 | uk.finance.yahoo.comAptose Biosciences, Inc.: Aptose Biosciences Announces Rescheduling of Special Meeting of Shareholders to Approve the Acquisition by Hanmi Pending Final Clearance from SECDecember 20, 2025 | finanznachrichten.deAptose reschedules special meeting on Hanmi acquisition planDecember 20, 2025 | msn.comAptose’s Tuspetinib Exceeds Expectations When Combined with Standard of Care Treatment Across Diverse Populations of Newly Diagnosed AMLOctober 16, 2025 | finance.yahoo.comAptose Biosciences Inc. (APS.TO) - Yahoo FinanceJuly 3, 2025 | ca.finance.yahoo.comSee More Headlines APS Stock Analysis - Frequently Asked Questions How have APS shares performed this year? Aptose Biosciences' stock was trading at C$2.12 at the beginning of 2026. Since then, APS stock has increased by 6.1% and is now trading at C$2.25. How were Aptose Biosciences' earnings last quarter? Aptose Biosciences Inc. (TSE:APS) issued its quarterly earnings results on Wednesday, May, 13th. The biotechnology company reported ($4.16) EPS for the quarter. When did Aptose Biosciences' stock split? Shares of Aptose Biosciences reverse split on Wednesday, February 26th 2025.The 1-30 reverse split was announced on Wednesday, February 26th 2025. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, February 26th 2025. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split. How do I buy shares of Aptose Biosciences? Shares of APS stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers. What other stocks do shareholders of Aptose Biosciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Aptose Biosciences investors own include Aptose Biosciences (APTO), Aurinia Pharmaceuticals (AUPH), NVIDIA (NVDA), Advanced Micro Devices (AMD), VistaGen Therapeutics (VTGN), BlackBerry (BB) and Micron Technology (MU). Company Calendar Last Earnings5/13/2026Today6/30/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeTSE SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolTSE:APS CIKN/A Webaptose.com Phone+1-647-4799828FaxN/AEmployees31Year FoundedN/AProfitability EPS (Trailing Twelve Months)C($10.41) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-C$154.69 million Net MarginsN/A Pretax MarginN/A Return on Equity115.24% Return on Assets-136.29% Debt Debt-to-Equity Ratio-98.74 Current Ratio0.55 Quick Ratio5.41 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowC$1.41 per share Price / Cash Flow1.60 Book ValueC($13.59) per share Price / Book-0.17Miscellaneous Outstanding Shares2,552,000Free FloatN/AMarket CapC$5.74 million OptionableNot Optionable Beta-1.38 7 Best Space Stocks to Own in 2026The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free Report This page (TSE:APS) was last updated on 6/30/2026 by MarketBeat.com Staff. From Our PartnersSPCX Warning - and Worst News for Stocks in 50 YearsGoldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ...TradeSmith | SponsoredThe startup growing 23 times faster than NvidiaAn official SEC document contains a name Elon Musk revealed on page 146 - a startup that one analyst believes ...Brownstone Research | SponsoredCODE RED: AI Meltdown Imminent?After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...Paradigm Press | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | Sponsored[Free Report] The 11-Hour Options Guide for Beginners - trade and ticker includedTired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredGold Is About to Do Something It Hasn’t in 90 YearsThe U.S. Treasury still carries America's gold reserves at $42 per ounce — a price set generations ago. Buried...US Gold Bureau | SponsoredPH: Do THESE 4 things to your bank account now …In a few short months, the US government could gain unprecedented powers over personal bank accounts - includi...Weiss Ratings | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aptose Biosciences Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aptose Biosciences With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free APS Stock Alerts